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Accumulation of advanced glycation end-products (AGEs) is thought to contribute to
muscle weakness in a diabetic animal model. Skin autofluorescence is a proposed marker
for accumulation of AGEs in the skin. We aimed to investigate the relationship between
AGEs accumulation, sarcopenia and muscle function of Japanese patients with type 1 dia-
betes. A total of 36 patients with type 1 diabetes participated in the present cross-sec-
tional study. Sarcopenia parameters (skeletal muscle mass index and knee extension
strength) were compared with subcutaneous AGEs accumulation using skin autofluores-
cence. The prevalence of sarcopenia and impaired knee extension strength was 16.6%
(men 0.0%, women 22.2%) and 47.2% (men 22.2%, women 55.6%), respectively. Knee
extension strength was negatively correlated with skin autofluorescence (r² = 0.14,
P < 0.05), but not with skeletal muscle mass index. In conclusion, the AGEs accumulation
might be one of the reasons of impaired lower limb muscle function in Japanese patients
with type 1 diabetes.
INTRODUCTION
Sarcopenia is characterized by loss of skeletal muscle mass and
its function1,2, and is associated with aging1. The prevalence
rates of sarcopenia in people aged 65–74 years are 2.3% in
men and 5.0% in women, whereas those in people aged 75–
84 years are 15.3% in men and 11.7% in women in a healthy
Japanese population3. Sarcopenia has recently been recognized
as one of the complications of type 2 diabetes4,5. However,
there have been no reports on the prevalence of sarcopenia in
patients with type 1 diabetes.
Advanced glycation end-products (AGEs), the products of
non-enzymatic binding of glucose and proteins, accumulate in
various tissues in older adults6. Chronic hyperglycemia acceler-
ates the AGEs accumulation, and increases the risk of diabetic
vascular complications, such as macroangiopathy and microan-
giopathy7–11. A previous study suggested that hyperglycemia
was associated with lower muscle function in middle-aged and
older patients12. However, there have been no reports on the
relationship between the accumulation of AGEs in patients with
type 1 diabetes and a reduction of muscle function.
Skin autoﬂuorescence (AF) has been proposed as a marker
of AGEs accumulation in the skin13. Skin AF is strongly corre-
lated with the speciﬁc AGEs content in skin biopsies, as shown
in multiple validation studies14–17.
The aim of the present study was to ascertain the status of
sarcopenia, and compare it with clinical characteristics in Japa-
nese patients with type 1 diabetes. Furthermore, the relationship
between AGEs accumulation and reduced muscle function was
cross-validated.
MATERIALS AND METHODS
Study design and participants
The present study was approved by the ethical committee of
Tokushima University Hospital (approved #2281-1). TheReceived 13 June 2016; revised 21 September 2016; accepted 5 October 2016
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inclusion criteria of this study were outpatients with type 1 dia-
betes aged over 40 years at Tokushima University Hospital.
Written informed consent was obtained from all participants.
Patients who were taking steroids and those with myopathy,
severe peripheral neuropathy or motor function disorders were
excluded. A cross-sectional analysis was carried out for each set
of data obtained from July until October 2015. There were 36
participants, aged 42–75 years (men n = 9, women n = 27;
mean age 55.7 – 10.3 years (mean – SD); duration of disease
13.9 – 10.2 years).
Measures
Skeletal muscle mass was measured with a body composition
analyzer (In Body bioelectrical impedance analyzer; Bio
Space, Seoul, Korea) using multifrequency bioelectrical impe-
dance analysis. Skeletal muscle mass index (SMI) was calcu-
lated by dividing extremity skeletal muscle by height squared.
A previous validation study showed that lean body mass
evaluated by this device was highly correlated with the data
measured by dual-energy X-ray absorptiometry (intraclass
correlation coefﬁcient: men = 0.96 and women = 0.95, respec-
tively)18.
Muscle function measurements included grip strength, knee
extension strength and gait speed. Grip strength and knee
extension strength were measured using handheld dynamome-
ters (T.K.K5401; Takei Scientiﬁc Instruments, Tokyo, Japan;
and l-tus F-100; ANIMA, Tokyo, Japan). A previous validation
study showed that interrater reliability of isometric knee exten-
sion strength measurements was highly correlated with the data
measured by the handheld dynamometers (intraclass correlation
coefﬁcient: men and women = 0.99, respectively)19. Gait speed
was measured using a stopwatch in time units of 0.01 s. Partic-
ipants were asked to walk straight ahead for 11 m at their
usual walking speed. The walking speed was measured at the
middle 5 m. Measurements were carried out twice and the fas-
ter speed (m/s) was recorded20. Muscle morphology and physi-
cal functional parameters were applied to the Asian Working
Group for Sarcopenia diagnostic algorithm to identify sarcope-
nia20. The cut-off values for sarcopenia were SMI <7.0 and
<5.7 kg/m2 for men and women, respectively, grip strength
<26 and <18 kg for men and women, respectively, and gait
speed <0.8 m/s. Also, the cut-off value that shows a low value
for lower limb muscle strength was set as <0.3 kg/kg of body
weight (kg/kgBW) for both men and women20–22. Glycated
hemoglobin (HbA1c) was measured with high-performance liq-
uid chromatography. HbA1c was expressed as a National Gly-
cohemoglobin Standardization Program equivalent value. Blood
pressure was measured in the upper arm, in the supine posi-
tion. Skin AF was measured with the AGE ReaderTM (DiagnOp-
tics Technologies BV, Groningen, the Netherlands), a device
that estimates AGEs skin accumulation using AGEs ﬂuorescent
properties13. A previous study showed that repeated skin AF
measurements on 1 day show an overall Altman error rate of
5.03%14.
Statistical analysis
Spss Statistics 22 (IBM Japan, Tokyo, Japan) was used for sta-
tistical processing. All data are presented as the mean – SD.
Relationships among age, diabetes duration, skin AF, HbA1c,
SMI and physical function parameters were determined using
the Pearson’s correlation coefﬁcient. Statistical signiﬁcance was
deﬁned as a P-value <0.05.
RESULTS
The physical characteristics of the participants are shown in
Table 1. The presence of hypertension, SMI and grip strength
were signiﬁcantly lower in women than in men. Of the patients
with type 1 diabetes, 16.6% (men 0.0%, women 22.2%) were
diagnosed as sarcopenia according to the Asian Working
Group for Sarcopenia criteria19 (Table 2). The prevalence of
SMI, grip strength, gait speed and lower limb strength below
the cut-off value was 16.6% (men 0.0%, women 22.2%), 25.0%
(men 11.1%, women 29.6%) 8.3% (men 0.0%, women 11.1%)
and 47.2% (men 22.2%, women 55.6%), respectively.
There was no signiﬁcant correlation between knee extension
strength and SMI. Knee extension strength was negatively cor-
related with duration of diabetes (r² = 0.16, P < 0.05) and
skin AF (r² = 0.14, P < 0.05), but not with HbA1c (Figure 1).
SMI was negatively correlated with age (r² = 0.17, P = 0.01),
but not HbA1c, skin AF or duration of diabetes. Skin AF
was not correlated with age and duration of diabetes. Multiple
regression analyses were carried out using knee extension
strength/weight and SMI indices as dependent variables, and
age, estimated glomerular ﬁltration rate, dyslipidemia, hyper-
tension, neuropathy, retinopathy, cardiovascular disease and
skin AF as independent variables. Skin AF was negatively
associated with knee extension strength/weight (b = -0.37,
P = 0.03).
DISCUSSION
The aim of the present study was to investigate the prevalence
rate of sarcopenia in patients with type 1 diabetes, and to vali-
date the relationship between AGEs accumulation and reduced
muscle function.
Compared with the previous report by Yuki et al.3, the
prevalence of sarcopenia in patients with type 1 diabetes in the
present study, where the mean age was 55.7 – 10.3 years, was
unexpectedly higher, and the proportion of women was mark-
edly higher. Furthermore, the percentage of participants whose
grip strength values were below the cut-off values was higher
than that found by Yuki et al.3 In addition, the prevalence of
participants whose knee extension strength was less than the
cut-off value was very high (47.2%).
Muscle mass has been reported to correlate with muscle
function in healthy individuals23,24. However, there was no sig-
niﬁcant correlation between knee extension strength and SMI
in the present study. This possibility suggests that muscle func-
tion is impaired independently from age-related reduction of
muscle mass in patients with type 1 diabetes.
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In contrast, skin AF and the duration of disease had a signif-
icant negative correlation with knee extension strength. HbA1c
levels had an insigniﬁcant negative correlation with knee exten-
sion strength. Previous reports have shown that the accumula-
tion of AGEs in fast twitch muscle ﬁbers cross-links muscle
collagen, hardens muscle stiffness and reduces the tonic force
of muscle contraction25–27. Several studies suggested that muscle
function declined with accumulation of AGEs in patients with
type 2 diabetes mellitus28, and healthy middle-aged29 and older
people30. Sugisawa et al.31 reported that skin AF reﬂects inte-
gration of past long-term glycemic control in patients with type
1 diabetes. Taken together, the results of the present study sug-
gest that sustained hyperglycemia associated with long duration
of disease and accumulation of AGEs could be involved as a
mechanism in the impaired muscle function together with
aging in patients with type 1 diabetes. However, there was no
correlation between SMI and skin AF. Because a signiﬁcant
negative correlation between the SMI and age was observed,
skin AF was not associated with lower muscle mass in patients
with type 1 diabetes. Skin AF and age were independent factors
for knee extension strength/weight and SMI, respectively.
The limitations of the present study were that the study
design was cross-sectional without control subjects, so we were
not able to achieve detailed veriﬁcation of sarcopenia incidence,
along with muscular dysfunction and the inﬂuence of AGEs
accumulation in the muscular tissue of type 1 diabetes patients.
We were also unable to evaluate the inﬂuence of lifestyle, dia-
betic complications (such as neuropathy) and pharmacotherapy
Table 2 | Prevalence of sarcopenia and cut-off value parameters
All Male Female
Prevalence of sarcopenia (%) 16.6 0.0 22.2
SMI ≤ cut-off value (%) 16.6 0.0 22.2
Grip strength ≤ cut-off value (%) 25.0 11.1 29.6
Knee extension strength/weight
≤ cut-off value (%)
47.2 22.2 55.6
Gait speed ≤ cut-off value (%) 8.3 0.0 11.1
SMI, skeletal muscle mass index.
Table 1 | Characteristics of type 1 diabetes patients
All Male Female
No. participants 36 9 27
Age (years) 55.7 – 10.3 53.8 – 7.8 56.3 – 11.0
Duration of diabetes (years) 13.9 – 10.2 13.9 – 10.3 14.2 – 10.9
BMI (kg/m2) 23.0 – 4.0 24.0 – 4.9 22.7 – 3.7
Systolic blood pressure (mmHg) 125 – 15 122 – 10 126 – 17
Diastolic blood pressure (mmHg) 72 – 10 77 – 11 70 – 9
HbA1c (%) 7.6 – 1.3 7.4 – 1.1 7.6 – 1.4
Skin AF 2.49 – 0.41 2.43 – 0.36 2.50 – 0.43
eGFR (mL/min/1.73 m2) 76 – 23 72 – 29 77 – 21
≥90 mL/min/1.73 m2 (%) 22.2 22.2 22.2
60 to <90 mL/min/1.73 m2 (%) 58.3 33.3 66.7
30 to <60 mL/min/1.73 m2 (%) 16.7 33.3 11.1
<30 mL/min/1.73 m2 (%) 2.8 11.2 0.0
Serum creatinine (mg/dL) 0.81 – 0.43 1.1 – 0.6 0.71 – 0.34
Method of insulin delivery MDI/CSII (%) 11.1 11.1 11.1
Treatment with statin (%) 27.8 33.3 25.9
Treatment with ACE Inhibitor (%) 2.8 11.1 0.0
Treatment with ARB (%) 16.7 33.3 11.1
Presence of dyslipidemia (%) 36.1 44.4 33.3
Presence of hypertension (%) 36.1 66.7 25.9*
Presence of neuropathy 47.2 66.7 40.7
Presence of retinopathy, NDR/SDR/PPDR/PDR (%) 66.7/19.4/8.3/5.6 55.6/22.2/22.2/0.0 70.4/18.5/3.7/7.4
Presence of cardiovascular disease (%) 2.8 0.0 3.7
SMI (kg/m2) 6.7 – 1.1 8.0 – 1.1 6.3 – 0.8**
Grip strength (kg) 26.2 – 8.5 36.9 – 6.3 22.6 – 5.6***
Knee extension strength/weight (kg/kg BW) 0.30 – 1.00 0.36 – 0.10 0.28 – 0.09
Gait speed (m/s) 1.23 – 0.23 1.24 – 0.19 1.23 – 0.24
Data are shown as mean value – SD. P-value for sex difference: *P < 0.05, **P < 0.01, ***P < 0.001. ACE, angiotensin-converting enzyme; AF, aut-
ofluorescence; ARB, angiotensin II receptor blocker; BMI, body mass index; BW, bodyweight; CSII, continuous subcutaneous insulin infusion; eGFR,
estimated glomerular filtration rate; HbA1c, glycated hemoglobin; MDI, multiple daily injections; NDR, Non-diabetic retinopathy; PDR, proliferative dia-
betic retinopathy; PPDR, preproliferative diabetic retinopathy; SDR, simple diabetic retinopathy; SMI, skeletal muscle mass index.
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Figure 1 | The correlation between knee extension strength/weight, skeletal muscle mass index (SMI) and clinical characteristics. (a,b) Age, (c,d)
duration of diabetes, (e,f) glycated hemoglobin (HbA1c) and (g,h) skin autofluorescence (AF) in male (open circle) and female (closed circle)
patients with type 1 diabetes. BW, bodyweight.
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of patients with type 1 diabetes on the decline of muscle
strength. These are the topics for future investigations. Finally,
another limitation was the small sample size of the analyzed
participants in the present study.
In conclusion, the present study shows that the prevalence
rate of lower limb muscular dysfunction was higher than sar-
copenia in Japanese patients with type 1 diabetes. The AGEs
accumulation might be one of the reasons for impaired lower
limb muscle function in these patients.
ACKNOWLEDGMENT
We acknowledge Ineko Takikawa for excellent secretarial work.
DISCLOSURE
The authors declare no conﬂict of interest.
REFERENCES
1. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J
Gerontol A Biol Sci Med Sci 2000; 55: 16–24.
2. Santilli V, Bernetti A, Mangone M, et al. Clinical definition of
sarcopenia. Clin Cases Miner Bone Metab 2014; 11: 177–180.
3. Yuki A, Ando F, Otsuka R, et al. Epidemiology of sarcopenia
in elderly Japanese. J Phys Fitness Sports Med 2015; 4: 111–
115.
4. Umegaki H. Sarcopenia and diabetes: Hyperglycemia is a
risk factor for age-associated muscle mass and functional
reduction. J Diabetes Investig 2015; 6: 623–624.
5. Kim TN, Park MS, Yang SJ, et al. Prevalence and
determinant factors of sarcopenia in patients with type 2
diabetes: the Korean Sarcopenic Obesity Study (KSOS).
Diabetes Care 2010; 33: 1497–1499.
6. Goldin A, Beckman JA, Schmidt AM, et al. Advanced
glycation end products. Sparking the development of
diabetic vascular injury. Circulation 2006; 114: 597–605.
7. Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of
immunochemical advanced glycosylation end products
precedes and correlates with early manifestations of renal
and retinal disease in diabetes. Diabetes 1995; 44: 824–829.
8. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of
Maillard reaction products in skin collagen in diabetes and
aging. J Clin Invest 1993; 91: 2463–2469.
9. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction
products and their relation to complications in insulin-
dependent diabetes mellitus. J Clin Invest 1993; 91: 2470–
2478.
10. Monnier VM, Vishwanath V, Frank KE, et al. Relation
between complications of type I diabetes mellitus and
collagen-linked fluorescence. N Engl J Med 1986; 314: 403–
408.
11. Genuth S, Sun W, Cleary P, et al. Glycation and
carboxymethyllysine levels in skin collagen predict the risk
of future 10-year progression of diabetic retinopathy and
nephropathy in the diabetes control and complications trial
and epidemiology of diabetes interventions and
complications participants with type 1 diabetes. Diabetes
2005; 54: 3103–3111.
12. Kalyani RR, Metter EJ, Egan J, et al. Hyperglycemia predicts
persistently lower muscle strength with aging. Diabetes Care
2015; 38: 82–90.
13. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-
invasive assessment of advanced glycation endproduct
accumulation. Diabetologia 2004; 47: 1324–1330.
14. Meerwaldt R, Links T, Graaff R, et al. Simple noninvasive
measurement of skin autofluorescence. Ann N Y Acad Sci
2005; 1043: 290–298.
15. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as
a noninvasive marker of vascular damage in patients with
type 2 diabetes. Diabetes Care 2006; 29: 2654–2659.
16. Singh R, Barden A, Mori T, et al. Advanced glycation end-
products: a review. Diabetologia 2001; 44: 129–146.
17. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin
autofluorescence: a tool to identify type 2 diabetic patients
at risk for developing microvascular complications. Diabetes
Care 2008; 31: 517–521.
18. Ling CH, de Craen AJ, Slagboom PE, et al. Accuracy of
direct segmental multi-frequency bioimpedance analysis in
the assessment of total body and segmental body
composition in middle-aged adult population. Clin Nutr
2011; 30: 610–615.
19. Katoh M, Isozaki K. Reliability of Isometric Knee Extension
Muscle Strength Measurements of Healthy Elderly Subjects
Made with a Hand-held Dynamometer and a Belt. J Phys
Ther Sci 2014; 26: 1855–1859.
20. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus
report of the Asian Working Group for Sarcopenia. J Am
Med Dir Assoc 2014; 15: 95–101.
21. Manini TM, Clark BC. Dynapenia and aging: an update. J
Gerontol A Biol Sci Med Sci 2012; 67: 28–40.
22. Manini TM, Visser M, Won-Park S, et al. Knee extension
strength cutpoints for maintaining mobility. J Am Geriatr
Soc 2007; 55: 451–457.
23. Maughan RJ, Watson JS, Weir J. Strength and cross-
sectional area of human skeletal muscle. J Physiol 1983; 338:
37–49.
24. Fukunaga T, Miyatani M, Tachi M, et al. Muscle volume is a
major determinant of joint torque in humans. Acta Physiol
Scand 2001; 172: 249–255.
25. Snow LM, Thompson LV. Influence of insulin and muscle
fiber type in nepsilon- (carboxymethyl) -lysine accumulation
in soleus muscle of rats with streptozotocin-induced
diabetes mellitus. Pathobiology 2009; 76: 227–234.
26. Snow LM, Fugere NA, Thompson LV. Advanced glycation
end-product accumulation and associated protein
modification in type II skeletal muscle with aging. J
Gerontol A Biol Sci Med Sci 2007; 62: 1204–1210.
27. Haus JM, Carrithers JA, Trappe SW, et al. Collagen, cross-
linking, and advanced glycation end products in aging
human skeletal muscle. J Appl Physiol 2007; 103: 2068–2076.
ª 2016 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd J Diabetes Investig Vol. 8 No. 3 May 2017 381
S HO R T R E P O R T
http://onlinelibrary.wiley.com/journal/jdi Sarcopenia and AGEs in type 1 diabetes
28. Shah KM, Clark BR, McGill JB, et al. Relationship between
skin intrinsic fluorescence–an indicator of advanced
glycation end products-and upper extremity impairments in
individuals with diabetes mellitus. Phys Ther 2015; 95: 1111–
1119.
29. Momma H, Niu K, Kobayashi Y, et al. Skin advanced
glycation end product accumulation and muscle strength
among adult men. Eur J Appl Physiol 2011; 111: 1545–1552.
30. Dalal M, Ferrucci L, Sun K, et al. Elevated serum advanced
glycation end products and poor grip strength in older
community-dwelling women. J Gerontol A Biol Sci Med Sci
2009; 64: 132–137.
31. Sugisawa E, Miura J, Iwamoto Y, et al. Skin autofluorescence
reflects integration of past long-term glycemic control in
patients with type 1 diabetes. Diabetes Care 2013; 36: 2339–
2345.
382 J Diabetes Investig Vol. 8 No. 3 May 2017 ª 2016 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd
S H O R T R E P O R T
Mori et al. http://onlinelibrary.wiley.com/journal/jdi
